CIMERLI (ranibizumab-eqrn)
CIMERLI is indicated for the treatment of Neovascular Age-Related Macular Degeneration; Macular Edema Following Retinal Vein Occlusion; Diabetic Macular Edema; Diabetic Retinopathy; Myopic Choroidal Neovascularization.
How CIMERLI Works
Ranibizumab-eqrn works by binding to the receptor binding site of active forms of vascular endothelial growth factor A (VEGF-A). This binding prevents VEGF-A from interacting with its receptors, VEGFR1 and VEGFR2, on the surface of endothelial cells. By inhibiting this interaction, the drug reduces endothelial cell proliferation, the formation of new blood vessels, and vascular leakage. This mechanism targets the underlying processes that cause neovascularization and edema in the eye.
Details
- Status
- Prescription
- First Approved
- 2022-08-02
- Patent Cliff
- 2023
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CIMERLI Approval History
What CIMERLI Treats
5 indicationsCIMERLI is approved for 5 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Macular Edema Following Retinal Vein Occlusion
- Diabetic Macular Edema
- Diabetic Retinopathy
- Myopic Choroidal Neovascularization
CIMERLI Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
Pharmacists can substitute CIMERLI for Lucentis without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
CIMERLI Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CIMERLI
3 of 10FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CIMERLI FDA Label Details
Indications & Usage
FDA Label (PDF)CIMERLI is indicated for the treatment of Neovascular Age-Related Macular Degeneration; Macular Edema Following Retinal Vein Occlusion; Diabetic Macular Edema; Diabetic Retinopathy; Myopic Choroidal Neovascularization.
Track CIMERLI with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.